This represents a forecast very strong CAGR of 21.4% from 2021 to 208. LDOC’s most recent calculation was 0% as of March 31, 2021, so the firm needs significant improvement in this regard, per the table below:Īccording to a 2021 market research report by Grand View Research, the global market for patient engagement solutions was an estimated $15.1 billion in 2020 and is forecast to reach $71 billion by 2028. While the company is not in the business of selling software, using this metric is instructive. The Rule of 40 is a software industry rule of thumb that says that as long as the combined revenue growth rate and EBITDA percentage rate equal or exceed 40%, the firm is on an acceptable growth/EBITDA trajectory. The Selling and Marketing efficiency rate, defined as how many dollars of additional new revenue are generated by each dollar of Selling and Marketing spend, dropped to 1.7x in the most recent reporting period, as shown in the table below: Selling and Marketing expenses as a percentage of total revenue have trended lower as revenues have increased, as the figures below indicate:

The firm seeks relationships with patient care centers throughout China to source patient participants as well as physicians.īy the end of 2020, the company counted a network of 33 patient care centers in 28 provinces. LinkDoc has received at least $366 million in equity investment from investors including Digital Medical Technology, New Enterprise Associates, China Broadband Capital, Esta Investments Pte, Lifetech Company and Alibaba Health Technology Company. LinkSolutions - clinical trial matching service LinkData - longitudinal medical data system Management is headed by founder and Chief Executive Officer Tianze Zhang, who was previously an employee at Tencent and Alibaba and founded Truststone, which provides health information systems to pharmaceutical and medical institutions.

Company & Technologyīeijing, China-based LinkDoc was founded to develop an online community between physicians and cancer patients that helps provide care for patients, longitudinal medical data and patient-clinical trial matching services. The valuation expectation at IPO appears reasonable and for investors who are interested in a fast-growing physician/patient/life science company network in China, so the IPO is worth consideration. The firm provides an online oncology physician and patient engagement network in China. LinkDoc Technology Limited ( LDOC) has filed to raise $200 million in an IPO of its American Depositary Shares representing underlying Class A ordinary shares, according to an F-1/A registration statement. Onlyyouqj/iStock via Getty Images Quick Take

Tony zhang linkdoc education